Recently, the availability of protocols supporting genetic complementation of Eimeria has raised the 17 prospect of generating transgenic parasite lines which can function as vaccine vectors, expressing and 18 delivering heterologous proteins. Complementation with sequences encoding immunoprotective 19 antigens from other Eimeria spp. offers an opportunity to reduce the complexity of species/strains in 20 anticoccidial vaccines. Herein, we characterise and evaluate EtAMA1 and EtAMA2, two members of 21 the apical membrane antigen (AMA) family of parasite surface proteins from Eimeria tenella. Both 22 proteins are stage-regulated, and the sporozoite-specific EtAMA1 is effective at inducing partial 23 protection against homologous challenge with E. tenella when used as a recombinant protein vaccine, 24
confer heterologous protection, E. tenella parasites were complemented with EmAMA1, the 26 sporozoite-specific orthologue of EtAMA1 from E. maxima, coupled with different delivery signals to 27 modify its trafficking and improve antigen exposure to the host immune system. Vaccination of 28 chickens using these transgenic parasites conferred partial protection against E. maxima challenge, 29 with levels of efficacy comparable to those obtained using recombinant protein or DNA vaccines. In 30 the present work we provide evidence for the first known time of the ability of transgenic Eimeria to 31 induce cross protection against different Eimeria spp. Genetically complemented Eimeria provide a 32 powerful tool to streamline the complex multi-valent anticoccidial vaccine formulations that are 33 currently available in the market by generating parasite lines expressing vaccine targets from multiple 34 eimerian species. 35 36 HIGHLIGHTS 37  Eimeria tenella harbours four different stage-specific AMA1 paralogues. 38  EtAMA1, but not EtAMA2, is involved in sporozoite invasion. 39 from Eimeria maxima is sufficient to induce statistically significant partial protection against challenge 78 with E. maxima oocysts that is broadly equivalent to that obtained using the same antigen in other 79 vaccine platforms. 80
To date no cross-protective parasite antigens have been described, but several induce 81 between 30 and 70% immune protection against homologous Eimeria challenge when tested 82 experimentally with diverse delivery platforms (Blake and Tomley, 2014) . The most promising antigens 83 are derived from early endogenous stages of the Eimeria lifecycle (sporozoite and first generation 84 schizont), which correlates with the findings observed in naturally infected chickens, where these 85 stages induce the strongest anti-Eimeria immunity (McDonald et al., 1986 (McDonald et al., , 1988 . Several of these 86 antigens have critical roles in host-parasite interactions including proteins that traffic to the parasite 87 surface and beyond via the secretory microneme (MIC) organelles such as MIC2 (Sathish et al., 2011) , 88 MIC3 (Lai et al., 2011) , MIC4 (Witcombe et al., 2004) , and apical membrane antigen (AMA)1, which 89 achieves around 45% immunoprotective capacity against homologous challenge with E. maxima 90 (Blake et al., 2011; Li et al., 2013) or Eimeria brunetti (Hoan et al., 2014) . 91
AMAs are a family of proteins expressed by phylogenetically distinct classes of obligate 92 intracellular apicomplexans including species of Plasmodium and the zoonotic coccidian Toxoplasma 93 gondii, where they are regarded as strong vaccine candidates (Remarque et al., 2008; Zhang et al., 94 2015) . These proteins are critical for the formation and maintenance of the moving junction, a stable 95 focus of adhesion between parasite and host cell membranes through which the parasite glides into 96 its intracellular vacuole (Aikawa et al., 1978; Besteiro et al., 2009; Tyler and Boothroyd, 2011) . 97
Plasmodium falciparum AMA1 exhibits very high levels of genetic polymorphism which poses a major 98 challenge for vaccine development, hence recent trials have included co-administration of several 99
PfAMA1 allelic variants (Faber et al, 2016) . In contrast, a recent study of genetic variation in E. tenella 100 identified little intrinsic polymorphism at the ama1 locus ETH_00007745 (ToxoDB, (Blake et al., 2015) ) 101
and we now report similar findings for the locus in E. maxima (GenBank accession number FN813221). 102 (EtAMA2, ToxoDB Accesion number ETH_000048600) (Lal et al., 2009; Oakes et al., 2013) . More 105 recently, genomic and phylogenetic analysis defined four classes of AMA paralogues (AMA1-4) that 106 are conserved across haemosporine and coccidian apicomplexans, including Eimeria (Parker et al., 107 2016). Polyclonal antiserum against recombinant EtAMA1 were shown to have inhibitory effects on 108 sporozoite invasion of cultured cells (Jiang et al., 2012) , however the serum reacted on western blots 109 and IFAT with both sporozoite and merozoite antigens, suggesting either that EtAMA1 protein is 110 expressed by both parasite stages or that the serum recognises more than one AMA paralogue. In this 111 paper we have clarified the stage-specific nature of these two dominant AMAs expressed by E. tenella 112 and show that whilst sporozoite-specific EtAMA1 induces partial immunoprotection against 113 homologous parasite challenge, merozoite-specific EtAMA2 does not. 114
The focus of the present work was thus two-fold. First, to characterise and test the potential 115 of the two most abundantly expressed AMA paralogues of E. tenella (EtAMA1 and EtAMA2) as 116 recombinant vaccines against homologous challenge (E. tenella) in chickens. Subsequently, armed 117 with the information that vaccination with EtAMA1, but not EtAMA2, significantly reduces the ability 118 of E. tenella challenge parasites to replicate, we generated transgenic populations of E. tenella that 119 express the orthologous sporozoite-specific AMA1 protein from E. maxima and tested these as live 120 vectored vaccines, showing that they confer a similar level of partial protection against heterologous 121 challenge (E. maxima). These results confirm the vaccine potential of AMA antigens for coccidiosis and 122 offer new opportunities for the development of multivalent vaccines against all the Eimeria spp. with 123 relevance to the poultry industry. 124 125 126 127 nylon wool and DE-52, using standard methods (Shirley et al., 1995) . Second generation merozoites 135 from E. tenella parasites were recovered from the intestines of chickens 112 h p.i. by trypsinisation 136 (Shirley et al., 1995) . Apical organelles (micronemes and rhoptries) were isolated from sporozoites 137 and purified by sucrose-density ultracentrifugation as previously described (Kawazoe et al., 1992 
Generation of polyclonal antibodies against EtAMA1 and EtAMA2 171
Hyperimmune antisera were raised in mice (EtAMA1 and EtAMA2), chickens (EtAMA1 only), 172 or rabbits (EmAMA1) against HisTrap FF purified recombinant proteins (see Section 2.4and (Blake et 173 al., 2011) ). Groups of three or four animals were immunised three times at fortnightly intervals with 174 between 10 and 50 µg of soluble antigen suspended in 100 µl of PBS and mixed with an equal volume 175 of Titremax gold (first immunisation) or Freund's incomplete adjuvant (second and third 176 immunisations) (Kawazoe et al., 1992) . Animals were bled 7 days after the second and third 177 immunisations and all sera screened by western blotting against solubilised whole sporozoite and 178 merozoite proteins.
Indirect immunofluorescence (IFAT) 180
Purified E. tenella sporozoites were fixed in 3% paraformaldehyde in PBS for 10 min then 20 181 µL spots of the suspension were dried onto glass coverslips. Dried parasites were permeabilised by 182 immersion in ice-cold methanol for 5 min, followed by rehydration in PBS for 20 min. IFAT was carried 183 out as described (Bumstead and Tomley, 2000) using antiserum to EtAMA1 or EtAMA2. The DNA stain 184 DAPI (4', 6'-diamidino-2 phenylindole) was included in the second antibody incubation step. Coverslips 185 were air dried, mounted on Vectashield (Vector Laboratories, Peterborough, UK) and photographed 186 at ×1,000 magnification under UV light using a Leitz fluorescence microscope. Alternatively, tissue 187 sections of infected caeca containing second generation schizonts as used for merozoite harvest were 188 de-waxed and pressure cooked. All samples were treated with PBS-1% BSA to block non-specific 189 staining, exposed to primary antibody for 1 h and then, after washing, were incubated with FITC-190 conjugated anti-chicken or anti-mouse-IgG (Sigma-Aldrich). Some samples were counterstained with 191 DAPI prior to examination. Coverslips and sections were examined with a Zeiss Axioskop microscope, 192 and pictures were taken with a cooled CCD camera using Improvision Openlab software. 193 194
In vitro secretion assays 195
Freshly excysted E. tenella H sporozoites were purified, resuspended at 10 8 /ml in HAMs F9 196 media (Sigma-Aldrich) with or without 1% FCS supplementation (Sigma-Aldrich), and incubated at 41 197 ºC. Supernatants were removed at 0, 10 and 30 min post-incubation, clarified by centrifugation at 198 10,000 g for 10 min at 4 ºC, and then stored at -20 ºC until examined by SDS-PAGE and western blotting 199 (as described in Section 2.10). Rabbit antiserum against the E. tenella microneme protein 3 (EtMIC3) 200 was used as a positive control for secretion (Lai et al., 2011) and against the E. tenella heat shock 201 protein 70 (EtHSP70) protein as a control for inadvertent sporozoite lysis (Dunn et al., 1995; Bumstead 202 and Tomley, 2000) . 203 preparations were emulsified with Freund's incomplete adjuvant (Sigma-Aldrich). At 7 weeks of age, 232 birds were moved into single cages and each chicken was given an oral dose of 250 sporulated E. 233 tenella H strain oocysts to quantify the effect of the vaccine on parasite replication. Daily faecal 234 samples were collected from each bird from 5 to 12 days after challenge and the number of oocysts 235 excreted in the faeces calculated by counting of samples following a standard protocol (Long et al., 236 1976 ). Data were analysed by one-way ANOVA with a Tukey's post-hoc test using the GraphPad Prism 237 software (version 7.02). The coding sequence of the EmAMA1 ectodomain was cloned into the XbaI site of the three 271 core constructs and therefore fused to the mCherry reporter ( Fig. 1 ). For this purpose, the pGEM-T-272
EmAMA1 plasmid was digested with XbaI (New England BioLabs) following the manufacturer's 273 protocol, and the XbaI-EmAMA1-XbaI insert was purified from agarose gels as described above. The 274 three core constructs were also digested with XbaI (single restriction site), treated with calf intestinal 275 alkaline phosphatase (New England BioLabs) according to the manufacturer's instructions, and 276 purified from agarose gels. The ligation of the EmAMA1 sequence into the core plasmids was carried 277 out using the T4 ligase (Promega) as detailed by the manufacturer. The three new constructs were 278 also propagated in XL1-Blue competent cells, mini-prepped, characterized by restriction analyses to 279 determine the insertion directionality using the NdeI enzyme (New England BioLabs), and sequenced 280 to check that the insert reading frame had not been altered by cloning. Facility, Edinburgh, UK) were split into six groups of seven in independent wire-floored cages (Table  327 2). One (Group 1, Et[EmAMA1-Ch]) and two (Group 3, Et[SP2-EmAMA1-Ch-GPI]) chicks were removed 328 prior to the start of the vaccination trial for husbandry reasons. Birds from groups 1 to 4 were 329 immunised by oral gavage at days 2, 8, 14 and 21 of age with 100, 500, 3,000, and 5,000 FACS enriched 330
transgenic EmAMA1 E. tenella sporulated oocysts, respectively, to mimic parasite recycling, whereas 331 birds from groups 5 to 6 were inoculated with sterile PBS following the same scheme. At day 30, birds 332 from groups 1 to 5 were challenged with 300 oocysts of the E. maxima W strain to quantify the effect The protein sequences of EtAMA1 and EtAMA2 were compared using the BLOSUM62 matrix, 388 and displayed low identity and similarity scores (0.338 and 0.474, respectively) ( Supplementary Fig.  389 S1). Samples of unsporulated oocysts (UO, 1.25×10 5 /well), sporulated oocysts (SO, 1.25×10 5 /well), 390 sporozoites (Sz, 1×10 6 /well) and second generation merozoites (Mz2, 1×10 6 /well) were probed with 391 hyperimmune mouse serum against rEtAMA1 or rEtAMA2. EtAMA1 was detected in the sporulated 392 oocyst and sporozoite lanes and was absent from the merozoites. Conversely, EtAMA2 was detected 393 only in merozoites ( Fig. 2A ). Subsequent comparison of RNAseq datasets representing UO, SO, Sz, 394
Mz2 and gametocyte (Gam) lifecycle stages confirmed these findings, with additional evidence of 395 stage-specific transcription for EtAMAs 1-4 (Table 3 ). Mean Ka/Ks ratios of less than 1.0 were reported 396 for AMA1 and AMA4, indicating purifying or stabilising selection. 397
Samples of sporozoites and gradient-enriched preparations of sporozoite micronemes and 398 rhoptries were probed with hyperimmune mouse and chicken sera raised against the same 399 preparation of rEtAMA1. The mouse antiserum recognised a single microneme protein of an apparent 400 molecular mass of ~63 kDa, whereas the chicken antiserum additionally reacted with a protein in the 401 rhoptry fraction of ~60 kDa (Fig. 2B) . EtMIC3 antiserum demonstrated that the rhoptry fraction was 402 not significantly contaminated with micronemes, and EtHSP70 antiserum (a common contaminant of 403 rhoptry fractions, (Dunn et al., 1995) ) demonstrated that the microneme fraction was not 404 contaminated with rhoptries. 405
Immunofluorescent antibody staining of sporozoites with mouse anti-rEtAMA1 showed an 406 apical localisation within the zoite (Fig. 2C) , whereas mouse anti-rEtAMA2 showed clear apical staining 407 of mature merozoites in caecal sections harvested 114 h p.i. with E. tenella H strain (when second 408 generation schizogony is underway) (Fig. 2C) . Some sections were counterstained with antibodies 409 against the merozoite surface antigen EtSAG4, to delineate the outline of merozoites within schizonts. 410
Others were counterstained with antibodies against EtMIC2 to delineate the micronemes.
Interestingly, EtAMA2 only partially co-localised with EtMIC2, indicating that it may not all be localised 412 within the microneme organelles or alternatively that the two proteins may be differentially 413 distributed within the microneme population (Fig. 2C) . A similar phenomenon was previously noted 414 when co-staining for EtAMA1 and EtMIC3 (Lai et al, 2011) . 415 EtAMA2, recombinant thioredoxin, anti rEtAMA2 serum, or anti-ENR serum did not affect uracil 425 uptake ( Fig. 2E) . 426 427
Recombinant EtAMA1 induces an immune response protective against E. tenella challenge 428
In experiment 1, vaccination with rEtAMA1 induced a significant reduction in oocyst output 429 after challenge with E. tenella (P < 0.05, one way ANOVA test), reducing oocyst shedding by 77.4% 430 compared with the non-vaccinated control, whereas no significant differences were found between 431 chickens vaccinated with rEtAMA2 and non-immunised animals (P > 0.05, one way ANOVA test) ( Fig.  432 3). Similarly, in experiment 2, vaccination with rEtAMA1 or with combined rEtAMA1+rEtAMA2 induced 433 a significant reduction in oocyst output after challenge with E. tenella (P < 0.05, one wayANOVA test), 434 reducing oocyst shedding by 76 and 66% compared with the non-vaccinated control, respectively. 435
Again, no significant differences were found between chickens vaccinated with rEtAMA2 and non-436 immunised animals (P > 0.05, one way ANOVA test) ( Fig. 3) .
Eimeria tenella can express the foreign antigen EmAMA1 and modify its trafficking when 438
complemented with appropriate delivery signals 439 Three populations of transgenic E. tenella parasites expressing EmAMA1 were generated by 440 transfection and stabilised by sequential passage through chickens medicated with pyrimethamine 441 (Fig. 4A ). The first round of infection resulted in shedding of 20 to 60×10 6 oocysts/bird 1 week p.i., of 442 which 1 to 2% expressed the mCitrine reporter. FACS enrichment of mCitrine expressing parasites 443 was ~95% efficient and successive in vivo passage of FACS isolated mCitrine-positive parasites under 444 pyrimethamine selection improved the transgenic proportion of each population from 1 to 2% at 445 passage 1, to 16 to 42% at passage 3 ( Fig. 4A) . 446
Transcription of EmAMA1 mRNA was confirmed by RT-PCR in all three transgenic populations 447 in the absence of gDNA contamination (Fig. 4C ). In addition, expression of the EmAMA1 protein was 448 indicated by detection of the fused mCherry reporter by fluorescence microscopy (Fig. 4B ). In the 449 three populations, FACS enriched parasites expressed mCitrine as a cytosolic protein, whereas the 450 expression pattern of mCherry differed among them. Parasites not complemented with delivery 451 signals expressed the mCherry as a cytosolic protein which co-localised with mCitrine (EmAMA1-Ch in 452 Fig. 4B ). In contrast, populations complemented with the SP2 sequence secreted the mCherry reporter 453 into the sporocyst cavity (SP2-EmAMA1-Ch and SP2-EmAMA1-Ch-GPI in Fig. 4B ). Furthermore, 454 complementation with the GPI-anchor additionally induced the anchorage of mCherry onto the 455 sporozoite surface (SP2-EmAMA1-Ch-GPI in Fig. 4B ). In all populations both mCitrine and mCherry 456 were present within cytosolic aggregates, which in some cases were co-localised (Fig. 4B) . 457 458
Vaccination with transgenic E. tenella expressing EmAMA1 protects against challenge by the 459 antigen donor E. maxima without eliciting specific humoral responses, but reducing serum IL-10 levels 460
Vaccination with live E. tenella parasites did not result in significant differences in weights 461 between groups prior to challenge (P > 0.05, one way ANOVA test) indicating no detrimental effect of 462 the vector. Similarly, no differences in body weight gain were found between groups after challenge with E. maxima W strain, as the dose used was deliberately low in order to accurately determine the 464 vaccination effect on parasite replication ((Blake et al., 2006); P > 0.05, one way ANOVA test) 465 ( Supplementary Fig. S2A and B) . Vaccination with all three transgenic E. tenella populations expressing 466
EmAMA1 resulted in significant reductions in oocyst output after challenge with E. maxima (P < 0.05, 467 one way ANOVA test), ranging from 45 to 55% compared with the non-vaccinated and the challenged 468 groups (Fig. 5A ). Pairwise comparisons did not show statistical differences between the three 469 vaccinated groups (P > 0.05, one way ANOVA test). 470
Serum samples collected 8 days after final vaccination (day 29) showed variable antibody 471 reactivity against rEmAMA1 protein within experimental groups, and no reactivity against native 472
EmAMA1 in E. maxima solubilised protein extracts, suggesting that the observed reduction in parasite 473 replication after challenge was not mediated by specific humoral responses against EmAMA1 (Fig. 5B) . 474
Similarly, we did not detect enhanced levels of IFN- in serum 8 days after final vaccination (day 29) 475 or 6 days after challenge (day 36), with equally low concentrations across all groups (under 60 pg/ml, 476 P > 0.05, one way ANOVA test) ( Fig. 5C ). At day 29, all groups displayed low levels of serum IL-10 (P > 477 0.05, one way ANOVA test) ( Fig. 5C ) and at 6 days post-challenge (day 36) the average IL-10 serum 478 levels were lower in all groups immunised with transgenic parasites compared with non-vaccinated 479 and challenged birds (Fig. 5C ). However this reduction was only significant in groups vaccinated with 480
Et[SP2-EmAMA1-Ch] and Et[SP2-Ch-GPI] parasites (P < 0.05, one way ANOVA test), suggesting that the 481 effect is not mediated by expression of EmAMA1. A positive correlation was detected between serum 482 IL-10 levels and oocyst output (64%, P < 0.001, Pearson correlation test, data not shown). 483 484
Sequence diversity for the anticoccidial vaccine candidate EmAMA1 is limited and comparable to 485 the E. tenella orthologue 486
Comparison of 56 E. tenella AMA1 coding sequences previously revealed limited antigenic 487 diversity and a largely neutral signature of selection (Blake et al., 2015) . Here, comparison of 18 revealed a comparably low level of diversity (Table 4) . Specifically, nine EmAMA1 cDNA haplotypes 490 were identified but total nucleotide diversity was low and no significant signatures of selection were 491 detected. Analysis of the 1,617 bp coding sequence alignment revealed 10 nucleotide substitutions, 492 of which three were non-synonymous. Substitutions of histidine to leucine (amino acid position 81), 493 isoleucine to methionine (position 133) and glutamic acid to aspartic acid (position 393) were 494 detected, of which the latter was located close to the glutamic acid to valine (position 386) 495 substitution described previously in the EtAMA1 amino acid sequence (Blake et al., 2015) . 496
Discussion 498
In the present work we have characterised the two most highly expressed AMAs of E. tenella, 499
EtAMA1 (ToxoDB Accession number ETH00007745) and EtAMA2 (ToxoDB Accession number 500 ETH00004860) and demonstrate, to our knowledge for the first time, that vaccination with sporozoite-501 specific EtAMA1, but not merozoite-specific EtAMA2, elicits highly significant protection against 502 homologous challenge with E. tenella. With this knowledge we went on to establish a proof of concept 503 for the use of Eimeria parasites as vaccine delivery vectors for heterologous coccidial antigens, 504
showing that E. tenella parasites expressing EmAMA1 antigen from E. maxima are able to induce 505 partial protection in all the vaccinated birds against heterologous challenge infection with E. maxima. 506 A polyclonal mouse serum raised against rEtAMA1 detected native EtAMA1 in sporulated 507 oocysts and sporozoites, but not in merozoites, and conversely mouse serum against rEtAMA2, 508 detected native EtAMA2 solely in merozoites. These results agree with previous proteomic and 509 transcriptomic data and confirm that these two EtAMA paralogues are tightly stage-regulated (Lal et 510 al., 2009; Reid et al., 2014) . Interestingly a second antibody raised against rEtAMA1 in chickens 511 detected an additional sporozoite protein (Fig. 2B) indicating the potential for cross-reactivity of anti-512 AMA1 antibodies. This additional protein was not identified, but it could potentially be EtAMA3 or 513
EtAMA4, both of which are expressed in the sporozoite stage (Table 3) . Importantly, we showed that reducing sporozoite invasion of cultured cells, in agreement with previous work (Jiang et al., 2012) , 516 whereas anti-rEtAMA2 and -rEtAMA2 protein had no effect on parasite invasion, again indicating the 517 highly stage-specific nature of the two paralogues. The possession of four AMA paralogs in T. gondii is 518 proposed to confer exceptional molecular plasticity at the parasite-host-cell interface (Poukchanski 519 et al., 2013; Lamarque et al., 2014; Parker et al., 2016) . In this work, we identified the EtAMA2 gene 520 in merozoite-derived expressed sequence tags (ESTs) (data not shown) supporting previous 521 observations based on transcriptomic data (Reid et al., 2014) , and confirmed that EtAMA2 protein is and modify the protein trafficking by inducing its secretion and tethering to the sporozoite surface. As 554 expected, all three transgenic populations transcribed the EmAMA1-mCherry sequence, expressed 555 the protein at high levels, and displayed differential secretion patterns (Fig. 4) . In previous work we 556
showed that E. tenella parasites expressing the yellow fluorescent protein (YFPmYFP) can be stabilized 557 after three generations under double selection (Clark et al., 2008) . In the present study, the same 558 number of in vivo passages was insufficient to obtain fully fluorescent populations, although all 559 populations displayed distinct increases in the percentage of stable transgenic parasites after three 560 generations (Fig. 4A) . We have observed this to be the case for several other co-transfections (data 561 not published), and hypothesise that it could be due to the disruption of the integrated plasmids 562 during sporulation, when meiosis takes place under no drug selection. 563
Previous studies have shown that the immunological activity of AMA1 in Plasmodium 564 parasites relies on its correct folding (Hodder et al., 2001 ). While we did not check whether EmAMA1 565 was properly folded in transgenic populations, we assumed that the use of an E. tenella-based vector 566 would support appropriate folding of foreign proteins from other Eimeria spp., and according to our data this seems to have been the case. We observed similar results in a previous study carried out 568 with birds that received single or trickle vaccinations with E. tenella Wis parasites expressing EmAMA1 569 under the control of the EtAMA1 promoter and displayed a reduction in the oocyst output ranging 570 from 38.4 to 46.9% after challenge with E. maxima W ( Supplementary Fig. S3 ). Furthermore, similar 571 cross-strain heterologous protection results were observed when E. maxima H strain sporozoites 572 transiently transfected with a bacterial artificial chromosome (BAC) construct carrying the EmAMA1 573 sequence from the E. maxima W strain were used as a vaccine (Blake et al., 2011) . All these data offer 574 promising prospects for the future development of anti-coccidial vaccines based on Eimeria as a 575
vector. 576
Interestingly, all three transgenic populations induced similar levels of heterologous 577 protection after challenge with E. maxima, suggesting that the EmAMA1 protein is similarly processed 578 by the host immune system regardless of the delivery signal employed. However, sera collected after 579 vaccination were consistently not reactive against the native EmAMA1 protein within E. maxima 580 protein extracts (Fig. 5B) . These findings correlate with our previous study, in which vaccination with 581 with transgenic E. tenella) or day 36 (6 days after challenge with E. maxima). We did not expect to see enhanced levels at day 29, as this was 4 weeks after the primary vaccination, but did expect to see 594 induction of serum IFN- at day 36, as this is reported to increase in serum at 8 days post challenge 595 with E. maxima (Yun et al., 2000) . However, an earlier report did not detect serum IFN- until 20 days 596 following primary and serial exposure to E. maxima (Yun et al., 2000) , thus the timing may vary 597 according to host strain and parasite dose. Similarly, the trickle vaccination did not affect IL-10 serum 598 levels at day 29 compared tocontrols (Fig. 5C) , and again this is most likely due to the timing of 599 sampling. In contrast, all challenged birds showed increased serum IL-10 levels at day 36, including 600 birds immunised with transgenic parasites. Expressed serum IL-10 was lower in all immunised birds 601 compared to non-immunised birds, irrespective of exposure to EmAMA1. Increased serum IL-10 at 602 day 36 in all challenged birds may be explained by exposure to different Eimeria spp. at immunisation 603 and challenge (transgenic E. tenella and E. maxima), effectively indicating different primary infections. 604
The lower serum IL-10 levels in birds immunised using Et[SP2-Ch-GPI] suggests a low level of cross-605 protection, which was reflected in oocyst output (17% to 27% reduction; Fig. 5B and Supplementary 606 Fig. S3 ). We also observed that increased serum IL-10 levels may lead to increased oocyst shedding, 607 which agrees with previous findings (Sand et al., 2016) , indicating that serum IL-10 levels could be a 608 potential predictive marker of susceptibility to infection (Wu et al., 2016) . 609
Previous studies have shown that fecundity of Eimeria parasites is reduced as the infective 610 dose increases due to a 'crowding effect', and infection with 250 oocysts is sufficient to induce the 611 highest level of oocyst shedding (Johnston et al., 2001; Williams, 2001) . For this reason, measurement 612 of oocyst replication after a low-dose challenge is the most sensitive method available for measuring 613 vaccine efficacy, and is still regarded as a 'gold standard' by vaccine regulators. However, this 614 approach is not suitable for evaluation of factors such as protection against intestinal damage (lesion 615 score) and body weight gain as shown by a recent study, where infections with similar doses of E. 616 maxima only induced mild lesions and very low body weight losses (Jenkins et al., 2017a) . Future trials 617 will be required to evaluate protection against more severe challenge doses.
The confirmation of limited genetic diversity between AMA1 alleles for E. maxima, with no 619 evidence of significant signatures of selection, mirrors that described previously for E. tenella (Blake 620 et al., 2015) . Antigenic diversity within parasite populations provides the potential for immune escape, 621 with the greatest likelihood when small numbers of antigens are used in subunit or recombinant 622 vaccines to induce focused immune responses. The low levels of naturally occurring diversity 623 described for EtAMA1 have enhanced its candidacy for use in novel anti-coccidial vaccines. While 624 AMA1 is known to be highly polymorphic within populations of some apicomplexans such as 625
Plasmodium falciparum (Takala and Plowe, 2009), the low levels of polymorphism and its ability to 626 induce immune protection described for two Eimeria spp. suggest that AMA1 is a viable vaccine 627 candidate for all Eimeria spp. which infect chickens, and possibly all Eimeria spp. 628
Currently the commercial availability of live vaccine formulations is constrained by inherent 629 limitations in the capacity of production of live parasites, which is especially true where attenuated 630 vaccines are produced (Williams, 1998). In the broiler sector, where profit margins are very tight, 631 control measures are still highly dependent on the use of anti-coccidial prophylaxis due to the higher 632 costs of these vaccines (Sharman et al., 2010; Blake and Tomley, 2014). Therefore, there is a need to 633 reduce the cost of the available formulations in the market and make them more attractive for this 634 sector. Herein we show that EtAMA1 is an effective vaccine candidate, provide evidence for the first 635 time that genetic complementation of E. tenella parasites is a valuable tool to deliver vaccine 636 candidates from other coccidian species which infect poultry, and demonstrate that this vaccine 637 platform is able to induce significant levels of heterologous protection after complementation with 638
EmAMA1. Furthermore, we provide a powerful tool to develop new generation vaccines against 639 multiple Eimeria spp. as a means to streamline the available formulations in the market, and thus 
